A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

The goal of this clinical study is to evaluate the safety and efficacy of GT801 injection in adult patients with relapsed/refractory CD19-positive B-cell hematologic malignancies and autoimmune hemolytic anemia. Interim analysis conducted when 2 patients complete primary endpoint measurement.

Trial Details

NCT ID
NCT07205315
Phase
EARLY_PHASE1
Sponsor
Grit Biotechnology
Status
RECRUITING
Cancer Type
Lymphoma
Interventions
  • GT801 Injection
Locations (sample)
  • Zhengzhou, Henan, China|34.75778,113.64861
  • Tianjin, Tianjin Municipality, China|39.14222,117.17667

Key Eligibility Criteria

  • Aged 18 to 75 years (inclusive), male or female;
  • Participants with refractory or relapsed acute B-cell lymphoblastic leukemia (B-ALL), Chronic Lymphocytic Leukemia (CLL), B-cell Non-Hodgkin's Lymp…
  • Disease progression or recurrence after at least second-line drug treatment;
  • CD19 positivity confirmed by flow cytometry and/or histopathology (excluding autoimmune hemolytic anemia);

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Lymphoma Trials on Trialify →